NASDAQ:SCPH - Scpharmaceuticals Stock Price, News & Analysis

Scpharmaceuticals trades on the NASDAQ under the ticker symbol "SCPH."

Scpharmaceuticals Inc (NASDAQ:SCPH) issued its earnings results on Wednesday, August, 7th. The company reported ($0.39) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.49) by $0.10. View Scpharmaceuticals' Earnings History.

Scpharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Scpharmaceuticals.

2 equities research analysts have issued 1-year price targets for Scpharmaceuticals' stock. Their predictions range from $5.00 to $5.00. On average, they expect Scpharmaceuticals' stock price to reach $5.00 in the next twelve months. This suggests that the stock has a possible downside of 20.8%. View Analyst Price Targets for Scpharmaceuticals.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scpharmaceuticals in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Scpharmaceuticals.

Media stories about SCPH stock have trended positive recently, InfoTrie reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Scpharmaceuticals earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the stock's share price in the next several days. View News Stories for Scpharmaceuticals.

Scpharmaceuticals saw a decline in short interest in the month of July. As of July 31st, there was short interest totalling 103,400 shares, a decline of 28.8% from the June 30th total of 145,200 shares. Based on an average daily volume of 78,200 shares, the short-interest ratio is presently 1.3 days. Currently, 1.2% of the shares of the company are short sold. View Scpharmaceuticals' Current Options Chain.

Some companies that are related to Scpharmaceuticals include Milestone Pharmaceuticals (MIST), BioSpecifics Technologies (BSTC), ImmunoGen (IMGN), CytomX Therapeutics (CTMX), Neptune Wellness Solutions (NEPT), Organogenesis (ORGO), Flexion Therapeutics (FLXN), Dova Pharmaceuticals (DOVA), Obseva (OBSV), CymaBay Therapeutics (CBAY), ChemoCentryx (CCXI), BioDelivery Sciences International (BDSI), Avedro (AVDR), Collegium Pharmaceutical (COLL) and Evolus (EOLS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Scpharmaceuticals investors own include Adamas Pharmaceuticals (ADMS), Progenics Pharmaceuticals (PGNX), Catalyst Pharmaceuticals (CPRX), Melinta Therapeutics (MLNT), Omeros (OMER), Selecta Biosciences (SELB), Clearside Biomedical (CLSD), Dynavax Technologies (DVAX), Exelixis (EXEL) and Fate Therapeutics (FATE).

(SCPH) raised $96 million in an initial public offering on Friday, November 17th 2017. The company issued 6,400,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

Scpharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Eversept Partners LP (0.94%), Vanguard Group Inc. (0.48%), Northern Trust Corp (0.36%), Alambic Investment Management L.P. (0.32%), Jacobs Levy Equity Management Inc. (0.20%) and Paloma Partners Management Co (0.16%). Company insiders that own Scpharmaceuticals stock include 5Am Partners Iv, Llc and Ra Capital Healthcare Fund Lp. View Institutional Ownership Trends for Scpharmaceuticals.

SCPH stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Parametric Portfolio Associates LLC, SG Americas Securities LLC and Northern Trust Corp. View Insider Buying and Selling for Scpharmaceuticals.

SCPH stock was bought by a variety of institutional investors in the last quarter, including Eversept Partners LP, Alambic Investment Management L.P., Paloma Partners Management Co, Jacobs Levy Equity Management Inc. and Morgan Stanley. Company insiders that have bought Scpharmaceuticals stock in the last two years include 5Am Partners Iv, Llc and Ra Capital Healthcare Fund Lp. View Insider Buying and Selling for Scpharmaceuticals.

Shares of SCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of SCPH stock can currently be purchased for approximately $6.31.

Scpharmaceuticals has a market capitalization of $117.24 million. The company earns $-29,440,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. Scpharmaceuticals employs 21 workers across the globe.View Additional Information About Scpharmaceuticals.

The official website for Scpharmaceuticals is http://www.scpharma.com/.

Scpharmaceuticals' mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The company can be reached via phone at 617-517-0730 or via email at [email protected]